董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James McCullough | 男 | Chief Executive Officer and Chairman of the Board | 56 | 78.01万美元 | 未持股 | 2024-09-30 |
| Fergus Fleming | 男 | Chief Technology Officer and Director | 57 | 42.57万美元 | 未持股 | 2024-09-30 |
| Erik Lium | 男 | Non-Executive Director | 56 | 2.40万美元 | 未持股 | 2024-09-30 |
| Christopher Mills | 男 | Non-Executive Director | 72 | 2.40万美元 | 未持股 | 2024-09-30 |
| Catherine Coste | 女 | Non-Executive Director | 58 | 6.81万美元 | 未持股 | 2024-09-30 |
| Daniel J. Levangie | 男 | Non-Executive Director | 73 | 6.50万美元 | 未持股 | 2024-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James McCullough | 男 | Chief Executive Officer and Chairman of the Board | 56 | 78.01万美元 | 未持股 | 2024-09-30 |
| Fergus Fleming | 男 | Chief Technology Officer and Director | 57 | 42.57万美元 | 未持股 | 2024-09-30 |
| Michael J. Donovan | 男 | Chief Medical Officer | 69 | 38.00万美元 | 未持股 | 2024-09-30 |
| Howard Doran | 男 | President | 63 | 未披露 | 未持股 | 2024-09-30 |
| Joel Jung | 男 | Interim Chief Financial Officer | 66 | 未披露 | 未持股 | 2024-09-30 |
董事简历
中英对照 | 中文 | 英文- James McCullough
-
自成立以来，James McCullough一直担任我们的联合创始人兼首席执行官。McCullough先生拥有在公共和私营部门建立新兴技术公司的领导经验，在生命科学行业拥有特定的专业知识。从2008年到2014年，他担任Exosome Diagnostics Inc.的首席执行官，该公司是一家风险投资支持的个性化医疗公司，开发癌症的非侵入性液体活检诊断技术，于2018年被Bio-TechneCorporation收购。自2014年以来，McCullough先生还担任Renwick Capital，LLC（一家管理咨询公司，专门协助新兴的梦百合技术公司进行战略规划和业务执行）的管理合伙人。他在波士顿大学（Boston University）获得学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
James McCullough,has served as Renalytix Plc co-founder and Chief Executive Officer since Renalytix Plc inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. From 2018 to 2021, Mr. McCullough also served as a managing partner of Renwick Capital, LLC, a managing consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School. - 自成立以来，James McCullough一直担任我们的联合创始人兼首席执行官。McCullough先生拥有在公共和私营部门建立新兴技术公司的领导经验，在生命科学行业拥有特定的专业知识。从2008年到2014年，他担任Exosome Diagnostics Inc.的首席执行官，该公司是一家风险投资支持的个性化医疗公司，开发癌症的非侵入性液体活检诊断技术，于2018年被Bio-TechneCorporation收购。自2014年以来，McCullough先生还担任Renwick Capital，LLC（一家管理咨询公司，专门协助新兴的梦百合技术公司进行战略规划和业务执行）的管理合伙人。他在波士顿大学（Boston University）获得学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
- James McCullough,has served as Renalytix Plc co-founder and Chief Executive Officer since Renalytix Plc inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. From 2018 to 2021, Mr. McCullough also served as a managing partner of Renwick Capital, LLC, a managing consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.
- Fergus Fleming
-
自成立以来，Fergus Fleming一直担任我们的首席技术官。Fleming自2013年6月起担任FF Consulting Limited总经理，为医疗设备和诊断公司提供产品开发和商业化支持。在此期间，他曾担任Oncomark Limited的业务开发主管（2016年11月至2018年10月），以及EKF Diagnostics plc的多种职务（2013年以来）。他在生命科学领域拥有超过30年的经验，包括在Baxter梦百合、Boston Scientific and Trinity Biotech Plc担任领导职务。Fleming先生在爱尔兰高威大学（University College Galway）获得理学学位。
Fergus Fleming,has served as Renalytix Plc Chief Technology Officer and as a member of Renalytix Plc Board since Renalytix Plc inception. Since June 2013, Mr. Fleming has served as Managing Director of FF Consulting Limited, where he has provided product development and commercialization support to medical devices and diagnostics companies. While working at FF Consulting Limited, Mr. Fleming has served as Head of Business Development for Oncomark Limited from November 2016 to October 2018, and served in a number of roles at EKF Diagnostics plc. Mr. Fleming has over 30 years of experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific and Trinity Biotech plc. Mr. Fleming received a degree in Science from University College Galway, Ireland. - 自成立以来，Fergus Fleming一直担任我们的首席技术官。Fleming自2013年6月起担任FF Consulting Limited总经理，为医疗设备和诊断公司提供产品开发和商业化支持。在此期间，他曾担任Oncomark Limited的业务开发主管（2016年11月至2018年10月），以及EKF Diagnostics plc的多种职务（2013年以来）。他在生命科学领域拥有超过30年的经验，包括在Baxter梦百合、Boston Scientific and Trinity Biotech Plc担任领导职务。Fleming先生在爱尔兰高威大学（University College Galway）获得理学学位。
- Fergus Fleming,has served as Renalytix Plc Chief Technology Officer and as a member of Renalytix Plc Board since Renalytix Plc inception. Since June 2013, Mr. Fleming has served as Managing Director of FF Consulting Limited, where he has provided product development and commercialization support to medical devices and diagnostics companies. While working at FF Consulting Limited, Mr. Fleming has served as Head of Business Development for Oncomark Limited from November 2016 to October 2018, and served in a number of roles at EKF Diagnostics plc. Mr. Fleming has over 30 years of experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific and Trinity Biotech plc. Mr. Fleming received a degree in Science from University College Galway, Ireland.
- Erik Lium
-
Erik Lium自2018年11月以来一直担任我们的董事会成员。Lium博士自2014年3月起在西奈山担任多个职位，目前是西奈山创新合作伙伴的总裁，以及西奈山健康系统的执行Vice President兼首席商业创新官。Lium博士在几个私人公司董事会代表Mount Sinai，之前担任Accelerate NY Seed Fund的投资审查委员会成员。Lium博士还担任Kantaro的董事会主席。加入Mount Sinai之前，Lium博士担任加州大学旧金山分校（University of California，San Francisco UCSF）的创新、技术与联盟助理副校长，湾区国家科学基金会I-Corps节点的UCSF首席研究员，以及研究助理副校长。Lium博士在LabVelocity Inc.于2004年被收购之前担任其总裁。他在加州大学旧金山分校的J.Michael Bishop实验室从事博士后研究，在哥伦比亚大学的Saul J.Silverstein博士实验室的细胞、分子和生物物理综合研究项目中获得博士学位，并在冈萨加大学获得生物学学士学位。
Erik Lium,has served as a member of Renalytix Plc Board of Directors since November 2018. Since March 2014, Dr. Lium has served in various roles at Mount Sinai, where he is currently the president of Mount Sinai Innovation Partners, and the executive vice president and chief commercial innovation officer of the Mount Sinai Health System. In addition to his service on the board Dr. Lium represents Mount Sinai on several private company boards and previously served as a member of the investment review committee for the Accelerate NY Seed Fund. Prior to joining Mount Sinai, Dr. Lium served in a number of role at the University of California, San Francisco ("UCSF"), including as the Assistant Vice Chancellor of Innovation, Technology & Alliances, Assistant Vice Chancellor of Research and principal investigator for the Bay Area National Science Foundation I-Corps node. Additionally, prior to its acquisition in 2004, Dr. Lium served as President of LabVelocity Inc. Mr. Lium pursued postdoctoral research at UCSF in the laboratory of J. Michael Bishop, M.D., earned a Ph.D. from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein, and holds a B.S. in Biology from Gonzaga University. - Erik Lium自2018年11月以来一直担任我们的董事会成员。Lium博士自2014年3月起在西奈山担任多个职位，目前是西奈山创新合作伙伴的总裁，以及西奈山健康系统的执行Vice President兼首席商业创新官。Lium博士在几个私人公司董事会代表Mount Sinai，之前担任Accelerate NY Seed Fund的投资审查委员会成员。Lium博士还担任Kantaro的董事会主席。加入Mount Sinai之前，Lium博士担任加州大学旧金山分校（University of California，San Francisco UCSF）的创新、技术与联盟助理副校长，湾区国家科学基金会I-Corps节点的UCSF首席研究员，以及研究助理副校长。Lium博士在LabVelocity Inc.于2004年被收购之前担任其总裁。他在加州大学旧金山分校的J.Michael Bishop实验室从事博士后研究，在哥伦比亚大学的Saul J.Silverstein博士实验室的细胞、分子和生物物理综合研究项目中获得博士学位，并在冈萨加大学获得生物学学士学位。
- Erik Lium,has served as a member of Renalytix Plc Board of Directors since November 2018. Since March 2014, Dr. Lium has served in various roles at Mount Sinai, where he is currently the president of Mount Sinai Innovation Partners, and the executive vice president and chief commercial innovation officer of the Mount Sinai Health System. In addition to his service on the board Dr. Lium represents Mount Sinai on several private company boards and previously served as a member of the investment review committee for the Accelerate NY Seed Fund. Prior to joining Mount Sinai, Dr. Lium served in a number of role at the University of California, San Francisco ("UCSF"), including as the Assistant Vice Chancellor of Innovation, Technology & Alliances, Assistant Vice Chancellor of Research and principal investigator for the Bay Area National Science Foundation I-Corps node. Additionally, prior to its acquisition in 2004, Dr. Lium served as President of LabVelocity Inc. Mr. Lium pursued postdoctoral research at UCSF in the laboratory of J. Michael Bishop, M.D., earned a Ph.D. from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein, and holds a B.S. in Biology from Gonzaga University.
- Christopher Mills
-
Christopher Mills自成立以来一直担任我们的董事会成员。Mills先生于2011年创立了Harwood Capital Management，该公司是他于1993年共同创立的前母公司J.O.Hambro Capital Management的继任者。他是North Atlantic小型公司Investment Trust plc的首席执行官兼投资经理，也是Harwood Capital Management Ltd的董事长兼首席执行官。此前，他曾担任Invesco MIM公司（在那里他曾担任北美投资和风险投资主管）、Samuel Montagu International公司的董事。Mills先生目前任职于多家上市公司的董事会，包括EKF Diagnostics plc，Surreserve Group plc，Augean plc和MJ Gleeson plc。Mills先生在吉尔霍尔大学（Guildhall University）获得商业研究学士学位。
Christopher Mills,has served as a member of Renalytix Plc Board of Directors since Renalytix Plc inception. Mr. Mills founded Harwood Capital Management in 2011, a successor company to its former parent company, J.O. Hambro Capital Management, which Mr. Mills co-founded in 1993. Mr. Mills is Chief Executive Officer and Investment Manager of North Atlantic Smaller Companies Investment Trust plc and Chairman and Chief Executive Officer of Harwood Capital Management Ltd. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University. - Christopher Mills自成立以来一直担任我们的董事会成员。Mills先生于2011年创立了Harwood Capital Management，该公司是他于1993年共同创立的前母公司J.O.Hambro Capital Management的继任者。他是North Atlantic小型公司Investment Trust plc的首席执行官兼投资经理，也是Harwood Capital Management Ltd的董事长兼首席执行官。此前，他曾担任Invesco MIM公司（在那里他曾担任北美投资和风险投资主管）、Samuel Montagu International公司的董事。Mills先生目前任职于多家上市公司的董事会，包括EKF Diagnostics plc，Surreserve Group plc，Augean plc和MJ Gleeson plc。Mills先生在吉尔霍尔大学（Guildhall University）获得商业研究学士学位。
- Christopher Mills,has served as a member of Renalytix Plc Board of Directors since Renalytix Plc inception. Mr. Mills founded Harwood Capital Management in 2011, a successor company to its former parent company, J.O. Hambro Capital Management, which Mr. Mills co-founded in 1993. Mr. Mills is Chief Executive Officer and Investment Manager of North Atlantic Smaller Companies Investment Trust plc and Chairman and Chief Executive Officer of Harwood Capital Management Ltd. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University.
- Catherine Coste
-
Catherine Coste自2020年9月起担任公司董事。Coste女士最近从德勤会计师事务所（Deloitte and Touche）退休，她是该公司的高级合伙人，并担任德勤（Deloitte&8217；）的生命科学行业执行领导。她曾担任公司和专业服务职务32年，领导全球金融、内部审计和运营团队。在Deloitte的职业生涯中，Coste女士直接参与了30多家生命科学公司，其中大多数是大型和中型上市公司。Coste女士还拥有丰富的上市公司董事会经验，经常每月出席多个董事会委员会会议。Coste女士还在Sarbanes-Oxley合规，企业风险分析和管理，网络风险评估，欺诈预防，IT系统分析和升级，内部控制和公司治理方面拥有丰富的经验。Coste女士是一名注册会计师。
Catherine Coste Ms. Catherine Coste served as a Director of the Company from September 2020 to June 2025. Ms. Catherine Coste retired from Deloitte and Touche LLP ("Deloitte"), an indtry leading audit, consulting, tax and advisory firm, in 2020, where she was a senior Partner and served as one of Deloitte's Life Sciences indtry executive leaders. During her career at Deloitte, Ms. Catherine Coste was directly involved with over 30 life science corporations, the majority of which re large cap and medium cap public corporations. Ms. Catherine Coste has served as an Independent Director at Minerva Surgical, Inc., a commercial stage medical technology company, since February 2021, where she is Chair of the Audit Committee and a Member of the Compensation Committee. Ms. Catherine Coste has also served as an Independent Director at Renalytix, plc(NASDAQ: RNLX), an artificial intelligence enable in vitro diagnostics company, since June 2023, where she Chairs the Audit Committee and is also a Member of the Renumeration Committee. Ms. Catherine Coste spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. She has extensive experience in Sarbanes Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls, and corporate governance. Ms. Catherine Coste is a Certified Public Accountant in California and holds a Bachelor of Science in Biness Administration with a foc on Accounting from California State University, Hayward. - Catherine Coste自2020年9月起担任公司董事。Coste女士最近从德勤会计师事务所（Deloitte and Touche）退休，她是该公司的高级合伙人，并担任德勤（Deloitte&8217；）的生命科学行业执行领导。她曾担任公司和专业服务职务32年，领导全球金融、内部审计和运营团队。在Deloitte的职业生涯中，Coste女士直接参与了30多家生命科学公司，其中大多数是大型和中型上市公司。Coste女士还拥有丰富的上市公司董事会经验，经常每月出席多个董事会委员会会议。Coste女士还在Sarbanes-Oxley合规，企业风险分析和管理，网络风险评估，欺诈预防，IT系统分析和升级，内部控制和公司治理方面拥有丰富的经验。Coste女士是一名注册会计师。
- Catherine Coste Ms. Catherine Coste served as a Director of the Company from September 2020 to June 2025. Ms. Catherine Coste retired from Deloitte and Touche LLP ("Deloitte"), an indtry leading audit, consulting, tax and advisory firm, in 2020, where she was a senior Partner and served as one of Deloitte's Life Sciences indtry executive leaders. During her career at Deloitte, Ms. Catherine Coste was directly involved with over 30 life science corporations, the majority of which re large cap and medium cap public corporations. Ms. Catherine Coste has served as an Independent Director at Minerva Surgical, Inc., a commercial stage medical technology company, since February 2021, where she is Chair of the Audit Committee and a Member of the Compensation Committee. Ms. Catherine Coste has also served as an Independent Director at Renalytix, plc(NASDAQ: RNLX), an artificial intelligence enable in vitro diagnostics company, since June 2023, where she Chairs the Audit Committee and is also a Member of the Renumeration Committee. Ms. Catherine Coste spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. She has extensive experience in Sarbanes Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls, and corporate governance. Ms. Catherine Coste is a Certified Public Accountant in California and holds a Bachelor of Science in Biness Administration with a foc on Accounting from California State University, Hayward.
- Daniel J. Levangie
-
Daniel J. Levangie，2010年7月以来曾担任董事。他目前是ATON Partners的的联合创始人兼经理，一家私人投资和管理咨询公司。联合创立 ATON Partners之前，2011年10月以来他是Dune Medical Devices的首席执行官，一家私营医疗设备公司；Constitution Medical Investors的联合创始人和管理合伙人，一家私人投资和产品开发公司于2013年7月被Roche Diagnostics公司收购。担任上述职位之前，他在Cytyc担任各种行政管理职位，直到Cytyc在2007年10月被Hologic收购。这些职位包括执行副总裁兼首席运营官、Cytyc Health Corporation的的首席执行官兼总裁，Cytyc Surgical Products Division的执行副总裁兼、首席商务官和总裁。他于1992年加入Cytyc公司之前，在雅培公司担任了许多的销售、营销和与管理职位，一个多元化的医疗保健公司。他目前是Insulet公司（医疗设备公司）和Liposcience公司（诊断公司）的董事。他此前担任ev3公司（医疗器械公司）和Hologic公司（诊断、成像系统和手术产品公司）董事。他是东北大学巴内特研究所的顾问委员会成员，是Excel特许学校的受托人。他获得了东北大学药学学士学位。
Daniel J. Levangie,has served as a member of Renalytix Plc Board of Directors since August 2021. Mr. Levangie is the co-founder of, and has served as manager of, ATON Partners, a private investment firm, since 2013 and as president and CEO of CereVasc, LLC, a medical device company, since September 2018. He has served on the Board of Directors of Exact Sciences Corporation (NASDAQ: EXAS) since 2010. From 2013 through 2017, Mr. Levangie served as president of Insulet Drug Delivery Systems and served as a lead director of Insulet Corporation. Prior to that, Mr. Levangie was chief executive officer of Dune Medical Devices, Inc. and co-founder and managing partner of Constitution Medical Investors, Inc., a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in 2013, and held executive management positions with Cytyc Corporation ("Cytyc") including executive vice president and chief operating officer, chief executive officer and president until the acquisition of Cytyc by Hologic, Inc. in 2007. He served on the board of Hologic from 2007 to 2009. Mr. Levangie received a B.S. in Pharmacy from Northeastern University. - Daniel J. Levangie，2010年7月以来曾担任董事。他目前是ATON Partners的的联合创始人兼经理，一家私人投资和管理咨询公司。联合创立 ATON Partners之前，2011年10月以来他是Dune Medical Devices的首席执行官，一家私营医疗设备公司；Constitution Medical Investors的联合创始人和管理合伙人，一家私人投资和产品开发公司于2013年7月被Roche Diagnostics公司收购。担任上述职位之前，他在Cytyc担任各种行政管理职位，直到Cytyc在2007年10月被Hologic收购。这些职位包括执行副总裁兼首席运营官、Cytyc Health Corporation的的首席执行官兼总裁，Cytyc Surgical Products Division的执行副总裁兼、首席商务官和总裁。他于1992年加入Cytyc公司之前，在雅培公司担任了许多的销售、营销和与管理职位，一个多元化的医疗保健公司。他目前是Insulet公司（医疗设备公司）和Liposcience公司（诊断公司）的董事。他此前担任ev3公司（医疗器械公司）和Hologic公司（诊断、成像系统和手术产品公司）董事。他是东北大学巴内特研究所的顾问委员会成员，是Excel特许学校的受托人。他获得了东北大学药学学士学位。
- Daniel J. Levangie,has served as a member of Renalytix Plc Board of Directors since August 2021. Mr. Levangie is the co-founder of, and has served as manager of, ATON Partners, a private investment firm, since 2013 and as president and CEO of CereVasc, LLC, a medical device company, since September 2018. He has served on the Board of Directors of Exact Sciences Corporation (NASDAQ: EXAS) since 2010. From 2013 through 2017, Mr. Levangie served as president of Insulet Drug Delivery Systems and served as a lead director of Insulet Corporation. Prior to that, Mr. Levangie was chief executive officer of Dune Medical Devices, Inc. and co-founder and managing partner of Constitution Medical Investors, Inc., a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in 2013, and held executive management positions with Cytyc Corporation ("Cytyc") including executive vice president and chief operating officer, chief executive officer and president until the acquisition of Cytyc by Hologic, Inc. in 2007. He served on the board of Hologic from 2007 to 2009. Mr. Levangie received a B.S. in Pharmacy from Northeastern University.
高管简历
中英对照 | 中文 | 英文- James McCullough
自成立以来，James McCullough一直担任我们的联合创始人兼首席执行官。McCullough先生拥有在公共和私营部门建立新兴技术公司的领导经验，在生命科学行业拥有特定的专业知识。从2008年到2014年，他担任Exosome Diagnostics Inc.的首席执行官，该公司是一家风险投资支持的个性化医疗公司，开发癌症的非侵入性液体活检诊断技术，于2018年被Bio-TechneCorporation收购。自2014年以来，McCullough先生还担任Renwick Capital，LLC（一家管理咨询公司，专门协助新兴的梦百合技术公司进行战略规划和业务执行）的管理合伙人。他在波士顿大学（Boston University）获得学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
James McCullough,has served as Renalytix Plc co-founder and Chief Executive Officer since Renalytix Plc inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. From 2018 to 2021, Mr. McCullough also served as a managing partner of Renwick Capital, LLC, a managing consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.- 自成立以来，James McCullough一直担任我们的联合创始人兼首席执行官。McCullough先生拥有在公共和私营部门建立新兴技术公司的领导经验，在生命科学行业拥有特定的专业知识。从2008年到2014年，他担任Exosome Diagnostics Inc.的首席执行官，该公司是一家风险投资支持的个性化医疗公司，开发癌症的非侵入性液体活检诊断技术，于2018年被Bio-TechneCorporation收购。自2014年以来，McCullough先生还担任Renwick Capital，LLC（一家管理咨询公司，专门协助新兴的梦百合技术公司进行战略规划和业务执行）的管理合伙人。他在波士顿大学（Boston University）获得学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
- James McCullough,has served as Renalytix Plc co-founder and Chief Executive Officer since Renalytix Plc inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. From 2018 to 2021, Mr. McCullough also served as a managing partner of Renwick Capital, LLC, a managing consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.
- Fergus Fleming
自成立以来，Fergus Fleming一直担任我们的首席技术官。Fleming自2013年6月起担任FF Consulting Limited总经理，为医疗设备和诊断公司提供产品开发和商业化支持。在此期间，他曾担任Oncomark Limited的业务开发主管（2016年11月至2018年10月），以及EKF Diagnostics plc的多种职务（2013年以来）。他在生命科学领域拥有超过30年的经验，包括在Baxter梦百合、Boston Scientific and Trinity Biotech Plc担任领导职务。Fleming先生在爱尔兰高威大学（University College Galway）获得理学学位。
Fergus Fleming,has served as Renalytix Plc Chief Technology Officer and as a member of Renalytix Plc Board since Renalytix Plc inception. Since June 2013, Mr. Fleming has served as Managing Director of FF Consulting Limited, where he has provided product development and commercialization support to medical devices and diagnostics companies. While working at FF Consulting Limited, Mr. Fleming has served as Head of Business Development for Oncomark Limited from November 2016 to October 2018, and served in a number of roles at EKF Diagnostics plc. Mr. Fleming has over 30 years of experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific and Trinity Biotech plc. Mr. Fleming received a degree in Science from University College Galway, Ireland.- 自成立以来，Fergus Fleming一直担任我们的首席技术官。Fleming自2013年6月起担任FF Consulting Limited总经理，为医疗设备和诊断公司提供产品开发和商业化支持。在此期间，他曾担任Oncomark Limited的业务开发主管（2016年11月至2018年10月），以及EKF Diagnostics plc的多种职务（2013年以来）。他在生命科学领域拥有超过30年的经验，包括在Baxter梦百合、Boston Scientific and Trinity Biotech Plc担任领导职务。Fleming先生在爱尔兰高威大学（University College Galway）获得理学学位。
- Fergus Fleming,has served as Renalytix Plc Chief Technology Officer and as a member of Renalytix Plc Board since Renalytix Plc inception. Since June 2013, Mr. Fleming has served as Managing Director of FF Consulting Limited, where he has provided product development and commercialization support to medical devices and diagnostics companies. While working at FF Consulting Limited, Mr. Fleming has served as Head of Business Development for Oncomark Limited from November 2016 to October 2018, and served in a number of roles at EKF Diagnostics plc. Mr. Fleming has over 30 years of experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific and Trinity Biotech plc. Mr. Fleming received a degree in Science from University College Galway, Ireland.
- Michael J. Donovan
自成立以来，MichaelJ.Donovan一直担任我们的首席医疗官。2011年11月以来，Donovan还担任Icahn School of Medicine at Mount Sinai实验病理学教授和生物库和病理学核心董事。除了在哈佛医学院（Harvard Medical School）和波士顿儿童医院（Boston Children&8217；s Hospital）的学术生涯外，Donovan博士还在生物技术行业拥有超过20年的经验，在Millennium Pharmaceuticals和Incyte Pharmaceuticals担任多个高级管理职位。他最近担任Vigilant Biosciences，Inc.的首席临床官、Metastat，Inc.的首席医疗官和Exosome Diagnostics，Inc.的首席医疗官。Donovan博士在罗格斯大学（Rutgers University）获得动物学学士学位、内分泌学硕士学位和细胞与发育生物学博士学位。他在新泽西大学（University of Medicine and Dentistry of New Jersey）获得医学博士学位。
Michael J. Donovan,has served as Renalytix Plc Chief Medical Officer since Renalytix Plc inception. Since November 2011, Donovan has also served as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mount Sinai. In addition to an academic career at Harvard Medical School and Boston Children's Hospital, Dr. Donovan has over 20 years' experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan received a B.S. in Zoology, an M.S. in Endocrinology and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his M.D. from the University of Medicine and Dentistry of New Jersey.- 自成立以来，MichaelJ.Donovan一直担任我们的首席医疗官。2011年11月以来，Donovan还担任Icahn School of Medicine at Mount Sinai实验病理学教授和生物库和病理学核心董事。除了在哈佛医学院（Harvard Medical School）和波士顿儿童医院（Boston Children&8217；s Hospital）的学术生涯外，Donovan博士还在生物技术行业拥有超过20年的经验，在Millennium Pharmaceuticals和Incyte Pharmaceuticals担任多个高级管理职位。他最近担任Vigilant Biosciences，Inc.的首席临床官、Metastat，Inc.的首席医疗官和Exosome Diagnostics，Inc.的首席医疗官。Donovan博士在罗格斯大学（Rutgers University）获得动物学学士学位、内分泌学硕士学位和细胞与发育生物学博士学位。他在新泽西大学（University of Medicine and Dentistry of New Jersey）获得医学博士学位。
- Michael J. Donovan,has served as Renalytix Plc Chief Medical Officer since Renalytix Plc inception. Since November 2011, Donovan has also served as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mount Sinai. In addition to an academic career at Harvard Medical School and Boston Children's Hospital, Dr. Donovan has over 20 years' experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan received a B.S. in Zoology, an M.S. in Endocrinology and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his M.D. from the University of Medicine and Dentistry of New Jersey.
- Howard Doran
Howard Doran，自2023年9月起担任Renalytix plc首席商务官。Doran先生从2018年6月至2021年10月担任OncoGenesis，Inc.的董事，之前从2015年7月至2018年10月担任CereVasc，LLC的董事。在此之前，Doran先生从2014年2月起担任LipoScience，Inc.的总裁兼首席执行官，直到2014年11月徕博科成功完成对LipoScience，Inc.的收购。在此之前，Doran先生于2010年6月至2014年1月担任早期体外诊断公司、Bloodhound Fully Integrated Hematology System开发商Constitution Medical，Inc.的总裁兼首席运营官。此前，Doran先生是Hologic，Inc.高级管理团队的成员，并曾担任Hologic全球诊断业务的总裁。2007年10月，在Hologic收购Cytyc公司时，Doran先生加入了Hologic的高级管理团队，他曾担任Cytyc价值5亿美元的体外诊断业务的高级副总裁兼业务部门主管。从1997年到2007年，他是Cytyc公司管理团队的重要成员，担任多个高级商业职务，职责日益增加，包括医生销售和市场营销、管理式护理计划以及实验室销售和市场营销。多兰先生获得了宾夕法尼亚西切斯特大学的管理学学士学位。
Howard Doran,was appointed President in April 2024 after previously serving as Chief Business Officer of Renalytix since September 1, 2023. Prior to joining Renalytix, Mr. Doran served as LipoScience, Inc's President and Chief Executive Officer until successful completion of LabCorp's acquisition of the company in November 2014. Preceding LipoScience, Mr. Doran was President and Chief Operating Officer of Constitution Medical, Inc., an early-stage in vitro diagnostics company and developer of the Bloodhound Fully Integrated Hematology System, which was acquired by Roche Diagnostics, Inc. in July 2013. Prior to Constitution Medical, Mr. Doran was a member of the senior executive team of Hologic, Inc. and served as President of Hologic's Global Diagnostics business. Mr. Doran joined the senior management team of Hologic in 2007 at the time of Hologic's acquisition of Cytyc Corporation, where he had been serving as Senior Vice President and Business Unit Director of Cytyc's $500 million in vitro diagnostics business. From 1997 through 2007, he was a key member of the management team of Cytyc Corporation during Cytyc's dramatic growth, serving in a number of senior commercial roles of increasing responsibility including physician sales and marketing, managed care initiatives and laboratory sales and marketing. Mr. Doran holds a Bachelor of Science degree in Management from West Chester University of Pennsylvania.- Howard Doran，自2023年9月起担任Renalytix plc首席商务官。Doran先生从2018年6月至2021年10月担任OncoGenesis，Inc.的董事，之前从2015年7月至2018年10月担任CereVasc，LLC的董事。在此之前，Doran先生从2014年2月起担任LipoScience，Inc.的总裁兼首席执行官，直到2014年11月徕博科成功完成对LipoScience，Inc.的收购。在此之前，Doran先生于2010年6月至2014年1月担任早期体外诊断公司、Bloodhound Fully Integrated Hematology System开发商Constitution Medical，Inc.的总裁兼首席运营官。此前，Doran先生是Hologic，Inc.高级管理团队的成员，并曾担任Hologic全球诊断业务的总裁。2007年10月，在Hologic收购Cytyc公司时，Doran先生加入了Hologic的高级管理团队，他曾担任Cytyc价值5亿美元的体外诊断业务的高级副总裁兼业务部门主管。从1997年到2007年，他是Cytyc公司管理团队的重要成员，担任多个高级商业职务，职责日益增加，包括医生销售和市场营销、管理式护理计划以及实验室销售和市场营销。多兰先生获得了宾夕法尼亚西切斯特大学的管理学学士学位。
- Howard Doran,was appointed President in April 2024 after previously serving as Chief Business Officer of Renalytix since September 1, 2023. Prior to joining Renalytix, Mr. Doran served as LipoScience, Inc's President and Chief Executive Officer until successful completion of LabCorp's acquisition of the company in November 2014. Preceding LipoScience, Mr. Doran was President and Chief Operating Officer of Constitution Medical, Inc., an early-stage in vitro diagnostics company and developer of the Bloodhound Fully Integrated Hematology System, which was acquired by Roche Diagnostics, Inc. in July 2013. Prior to Constitution Medical, Mr. Doran was a member of the senior executive team of Hologic, Inc. and served as President of Hologic's Global Diagnostics business. Mr. Doran joined the senior management team of Hologic in 2007 at the time of Hologic's acquisition of Cytyc Corporation, where he had been serving as Senior Vice President and Business Unit Director of Cytyc's $500 million in vitro diagnostics business. From 1997 through 2007, he was a key member of the management team of Cytyc Corporation during Cytyc's dramatic growth, serving in a number of senior commercial roles of increasing responsibility including physician sales and marketing, managed care initiatives and laboratory sales and marketing. Mr. Doran holds a Bachelor of Science degree in Management from West Chester University of Pennsylvania.
- Joel Jung
Joel Jung，于2024年5月被任命为临时首席财务官，在此之前，Jung先生于2020年7月至2024年2月期间在Minerva Surgical，Inc.担任首席财务官。Jung先生于2018年10月至2020年7月期间担任多家生命科学公司的财务顾问。2018年10月至2019年6月，Jung先生曾在uBiome，Inc.担任多个职位，包括2019年3月至2019年6月担任首席财务官。在此之前，Jung先生曾担任Counsyl，Inc.（已被Myriad Genetics, Inc.收购）、塞莱拉科技、Bionano Genomics, Inc.、AgraQuest，Inc.（已被拜耳作物科学收购）等四家公司的首席财务官。Jung先生拥有普渡大学航空工程学士学位和加州大学伯克利分校哈斯商学院工商管理硕士学位。
Joel Jung,was appointed Interim Chief Financial Officer in May 2024 and previously, Mr. Jung served as Chief Financial Officer at Minerva Surgical, Inc. from July 2020 to February 2024. Mr. Jung served as a financial consultant to several life sciences companies from October 2018 to July 2020. From October 2018 to June 2019, Mr. Jung held various positions at uBiome, Inc., including as Chief Financial Officer from March 2019 to June 2019. Prior to that, Mr. Jung served as the Chief Financial Officer for four companies including Counsyl, Inc. (acquired by Myriad Genetics, Inc.), Bionano Genomics, Inc., AgraQuest, Inc. (acquired by Bayer CropScience), and Celera Corporation. Mr. Jung holds a B.S. Degree in Aeronautical Engineering from Purdue University and an M.B.A. from the Haas School of Business at the University of California, Berkeley.- Joel Jung，于2024年5月被任命为临时首席财务官，在此之前，Jung先生于2020年7月至2024年2月期间在Minerva Surgical，Inc.担任首席财务官。Jung先生于2018年10月至2020年7月期间担任多家生命科学公司的财务顾问。2018年10月至2019年6月，Jung先生曾在uBiome，Inc.担任多个职位，包括2019年3月至2019年6月担任首席财务官。在此之前，Jung先生曾担任Counsyl，Inc.（已被Myriad Genetics, Inc.收购）、塞莱拉科技、Bionano Genomics, Inc.、AgraQuest，Inc.（已被拜耳作物科学收购）等四家公司的首席财务官。Jung先生拥有普渡大学航空工程学士学位和加州大学伯克利分校哈斯商学院工商管理硕士学位。
- Joel Jung,was appointed Interim Chief Financial Officer in May 2024 and previously, Mr. Jung served as Chief Financial Officer at Minerva Surgical, Inc. from July 2020 to February 2024. Mr. Jung served as a financial consultant to several life sciences companies from October 2018 to July 2020. From October 2018 to June 2019, Mr. Jung held various positions at uBiome, Inc., including as Chief Financial Officer from March 2019 to June 2019. Prior to that, Mr. Jung served as the Chief Financial Officer for four companies including Counsyl, Inc. (acquired by Myriad Genetics, Inc.), Bionano Genomics, Inc., AgraQuest, Inc. (acquired by Bayer CropScience), and Celera Corporation. Mr. Jung holds a B.S. Degree in Aeronautical Engineering from Purdue University and an M.B.A. from the Haas School of Business at the University of California, Berkeley.